Dina Chaya

Dina Chaya has had a varied career in the venture capital industry. In 2009, they began working as a Partner at NeoMed. In 2014, they were appointed as a Board Director at TOPIVERT LIMITED. In 2016, they became a Board Director at OXULAR LIMITED. In 2017, they became a Partner at Omega Funds. In 2018, they were appointed as a Board Director at Attenua, Inc. and also became a Member of the Venture Capital Platform Council at Invest Europe. In 2019, they were appointed as a Board Director at Imago BioSciences, Inc. In 2020, they became a Board Director at Spruce Biosciences. In 2021, they were appointed as a Board Director at Anjarium Biosciences. In 2022, they became a Board Director at Monks Investment Trust PLC.

Dina Chaya received their Chartered Financial Analyst Degree from CFA Institute in 2004. Between 1994 and 1997, they earned their PhD in Molecular & Cellular Biology of Development from Pierre and Marie Curie University. Prior to that, they obtained their DEA in the same field from the same university between 1993 and 1994. Dina also earned their MSc in Natural Sciences from University of Cambridge between 1990 and 1993.